脑胶质瘤患者血清microRNA-375 的 表达水平及临床意义

Serum miRNA-375 levels in patients with glioma and its relationship with clinical case characteristics and prognosis

摘要:

目的 探讨脑胶质瘤患者血清microRNA-375（miRNA-375）水平及其临床意义。方法 选择 2012 年1 月—2013 年12 月西安交通大学第一附属医院神经外科收治的脑胶质瘤患者120 例作为脑胶质瘤组， 选取同期该院健康体检群众120 例作为对照组。逆转录聚合酶链反应测定患者血清miRNA-375 水平，对两 组患者的临床资料进行比较分析。结果 脑胶质瘤组miRNA-375 相对表达量低于对照组（P <0.05）。术前 KPS 评分≥ 80 分、病理分级Ⅲ和Ⅳ级患者血清miRNA-375 水平低于术前KPS 评分<80 分、病理分级Ⅰ和 Ⅱ级患者（P <0.05）。Logistics 回归分析显示，血清miRNA-375 水平与脑胶质瘤术前KPS 评分[Ol ^ R=8.794 （95 CI ：2.016，18.426），P =0.000] 和病理分级[Ol ^ R=9.314（95 CI ：2.413，20.319），P =0.000] 相关。低表达 miRNA-375 患者总生存时间、无进展生存时间低于高表达miRNA-375 患者（P <0.05）。结论 脑胶质瘤 患者血清miRNA-375 水平降低，血清miRNA-375 水平与脑胶质瘤KPS 评分和病理分级有关，有望成为脑 胶质瘤诊断和预后判断的潜在标志物。

Abstract:

Objective To investigate the serum miRNA-375 level in patients with glioma and its clinical significance. Methods A total of 120 patients with neurosurgical glioma were selected as glioma group and 120 healthy were selected as control group from January 2012 to November 2013 in the First Affiliated Hospital of Xi’an Jiaotong University. The serum miRNA-375 levels were determined by real-time fluorescent quantitative reverse transcriptase chain reaction (RT-qPCR). Results The serum miRNA-375 levels in glioma group (0.48±0.09) was lower than those in control group (1.00±0.05) (t = 55.327, P = 0.000). The serum miRNA-375 levels of patients of preoperative KPS score ≥80 and pathological grade III-IV were lower than those of patients of preoperative KPS score <80 and pathological grade I-II (P < 0.05). Logistics results showed that serum miRNA-375 levels were significantly associated with preoperative KPS scores [Ol ^ R = 8.794 (95 CI: 2.016, 18.426), P = 0.000] and pathologic grades [Ol ^ R = 9.314 (95 CI: 2.413, 20.319), P = 0.000] of gliomas. The overall survival time and progression-free survival time of patients with low expression of miRNA-375 were lower than those of patients with high expression of miRNA-375 (P = 0.011, 0.009). Conclusion Serum miRNA-375 levels are decreased in patients with glioma. The serum miRNA-375 levels are associated with glioma KPS scores and pathological grades, and are expected to be potential markers for glioma diagnosis and prognosis.